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Abstract
Background: Insulin glargine (glargine) and premixed insulins (premix) are alternative insulin
treatments. This analysis evaluated glycaemic control in 528 patients with type 1 (n = 183) or type
2 (n = 345) diabetes, after switching from premix to a glargine-based regimen, using unselected
general practice (GP) data.
Methods:  Data for this retrospective observational analysis were extracted from a UK GP
database (The Health Improvement Network). Patients were required to have at least 12 months
of available data, before and after, switching from premix to a glargine-based regimen. The principal
analysis was the change in HbA1c after 12 months of treatment with glargine; secondary analyses
included change in weight, bolus usage and total daily insulin dose. Inconsistent reporting of
hypoglycemic episodes precludes reliable assessment of this outcome. Multivariate analyses were
used to adjust for baseline characteristics and confounding variables.
Results: Both cohorts showed significant reduction in mean HbA1c 12 months after the switch: by
-0.67% (p < 0.001) in the type 1 cohort and by -0.53% (p < 0.001) in the type 2 cohort (adjusted
data). The size of HbA1c improvement was positively correlated with baseline HbA1c; patients with
a baseline HbA1c ≥ 10% had the greatest mean reduction in HbA1c, by -1.7% (p < 0.001) and -1.2%
(p < 0.001), respectively. The proportion of patients receiving co-bolus prescriptions increased in
the type 1 (mean 24.6% to 95.1%, p < 0.001) and type 2 (mean 16.2% to 73.9%, p < 0.001) cohorts.
There was no significant change in weight in either cohort. Total mean insulin use increased in type
2 diabetes patients (from 0.67 ± 1.35 U/Kg to 0.88 ± 1.33 U/Kg, p < 0.001) with a slight decrease
in type 1 diabetes patients (from 1.04 ± 2.51 U/Kg to 0.98 ± 2.58 U/Kg, p < 0.001).
Conclusion: In everyday practice, patients with type 1 or type 2 diabetes inadequately controlled
by premix insulins experienced significant improvement in glycaemic control over 12 months after
switching to a glargine-based insulin regimen. These findings support the use of a basal-bolus
glargine-based regimen in patients poorly controlled on premix.
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Background
Achieving the recommended target for glycaemic control
(glycated haemoglobin [HbA1c] 6.5% to 7.0%) [1-7] in
patients with type 1 or type 2 diabetes is essential for
reducing the risk of serious diabetes-related complications
[8-10]. In type 1 diabetes this can only be achieved with
insulin therapy. For patients with type 2 diabetes, insulin
therapy is indicated after failure to achieve glycaemic con-
trol despite increasingly aggressive treatment with oral
antidiabetic drugs (OADs) that are prescribed in combi-
nation with lifestyle changes.
Of the available insulin preparations, premixed insulins
(premix), combine fixed ratios of short- and intermediate
acting insulins into a single formulation that are generally
injected once or twice daily. In general, premix insulins do
not mimic physiologic insulin profiles and a substantial
proportion of patients have sub-optimal glycaemic con-
trol [11]. Insulin glargine (glargine, Lantus®), a long-act-
ing basal insulin analogue, available in the UK since 2002,
has a prolonged and predictable absorption rate over 24
hours, without peak effects [12]. In insulin-naïve patients
with type 2 diabetes, glargine treatment combined with
OADs is associated with significantly lower HbA1c levels
and fewer episodes of symptomatic hypoglycaemia com-
pared with premix [13].
For patients who are inadequately controlled with premix,
switching to a glargine-based regimen may offer advan-
tages in terms of glycaemic control, tolerability and
patient satisfaction with treatment [14-16]. In a retrospec-
tive sub-analysis of the AT.LANTUS (A Trial comparing
Lantus Algorithms to achieve Normal blood glucose Tar-
gets in subjects with Uncontrolled blood Sugar with type
2 diabetes mellitus) study [16], including 686 patients
with type 2 diabetes taking premix at baseline, poorly con-
trolled patients who switched to glargine ± OADs/pran-
dial insulin showed significantly improved glycaemic
control and a low incidence of severe hypoglycaemia after
6 months on treatment. Consistent with these findings, a
12-week observational study [14] showed that patients
with type 2 diabetes who switched from premix to
glargine plus OAD showed significant improvement in
mean HbA1c (-1.1 ± 1.0%, p ≤ 0.001) and reduction in
body weight (-1.5 ± 3.3 kg, p ≤ 0.001). However, whether
these benefits extend to both type 1 and type 2 diabetes
patients in routine clinical practice has yet to be investi-
gated. Therefore, this retrospective analysis was performed
to evaluate the effect of switching from premix to a
glargine-based regimen on glycaemic control, body
weight and insulin use in patients with type 1 or type 2
diabetes in a daily practice setting.
Methods
Data source
The data were sourced from a large national computerised
medical record database known as The Health Improve-
ment Network (THIN), which includes data from 211 UK
primary care practices collected over a 15 year period from
about 5 million patients, of whom 2.34 million were
actively registered with a practice and prospectively fol-
lowed [17]. The THIN database is not supported by any
industrial sponsor, nor biased towards any particular dis-
ease group. THIN data on patient demographics, medical
history, test results and drug treatments are collected in a
non-interventional manner during daily record keeping
within the general practice. To ensure confidentiality of
patient information, the data are anonymised at the col-
lection stage using encrypted identifiers for the physician
and individual.
From data collected between July 2002 and December
2005, as described previously [18,19], 137,258 patients
were identified as diabetic based on a relevant medical
diagnosis using the Read code system [20] or prescription
of OADs. Diagnosis of diabetes was attributed in a step-
wise manner. For those few patients who did not have a
specific diagnosis of diabetes (but use of insulin), a diag-
nosis of type 2 diabetes was attributed if the patient had
received any non-insulin, diabetes-related medication,
otherwise type 1 diabetes was assumed. Overall, 90% of
patients were identified as having a diagnosis of type 2
diabetes. Ethical approval for this analysis was obtained
from the London Multiple Research Ethics Committee
(Number 06/MRE02/32) before commencing data extrac-
tion.
Individuals were included in the current analysis if a) they
had been prescribed premix for at least 12 months before
switching to glargine and b) they continued glargine with-
out a switch to another basal insulin for at least 12
months. Following a switch to glargine patients could
receive OADs and/or boluses of prandial insulin in addi-
tion to basal glargine. Information on associated comor-
bidities including myocardial infarction, stroke,
peripheral vascular disease, neuropathy, nephropathy,
and retinopathy was also extracted. Use of analogue and
human prandial insulins could not be distinguished from
information collected.
Design and outcome measures
This was a retrospective, 24-month, non-randomised
analysis. The principal analysis was glycaemic control
measured using HbA1c. Measurements were performed
locally in each centre and mean HbA1c values were calcu-
lated every 3 months before and after switching insulin
therapy using actual or linearly interpolated values.
Although much of the UK is currently HbA1c  DCCT-Cardiovascular Diabetology 2009, 8:9 http://www.cardiab.com/content/8/1/9
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aligned, and primary care practices use National Health
Service hospital laboratories which are members of qual-
ity assurance schemes, the degree of standardisation at the
time of data collection (2002–2006) is not known. How-
ever, our study depends on change in HbA1c and will thus
be less sensitive to differences in calibration between
assays. Secondary analyses included mean change in
weight (kg) calculated as for HbA1c, mean change in pre-
scribed daily insulin dose calculated as units prescribed
divided by the number of days covered by the prescrip-
tion, the proportion of patients using bolus prandial insu-
lin, and the percentage of patients achieving defined
HbA1c  levels. Self-reported episodes of hypoglycaemia
were recorded by general practitioners during each 3
monthly interval.
Statistical methods
Linear interpolation of missing data was performed where
a patient had at least 2 data measurements during each 12
month period (prior to and following switch) and data
was not missing during two consecutive 3 monthly inter-
vals. Unadjusted results for the principle (HbA1c) and sec-
ondary analyses used linearly interpolated data and were
summarised using descriptive statistics. For the unad-
justed results the mean change during the 12 month prior
to and following the switch was calculated. Comparisons
were performed using paired t-tests. Graphical analyses
were based on linearly interpolated data, which provides
a clearer graphical interpretation of the results.
For the principle analysis of change in HbA1c a multivari-
ate analysis using actual patient data was performed.
Actual patient data was preferred over interpolated values;
multivariate models constructed using the later showing
no appreciable effect on the model specification or statis-
tical inference. Data was evaluated using multiple linear
mixed regression analyses, adjusting for repeated meas-
ures per patient over time, with change in HbA1c relative
to time of insulin initiation as the dependent variable
with the following pre-defined (fixed-effects) exploratory
covariates; age, weight, sex, type of diabetes, number of
OADs used before commencing insulin, number of OADs
used in combination with insulin at initiation, disease
duration, presence of hypoglycaemia and associated co-
morbidities during the study.
Multivariate models were developed with SPSS for Win-
dows (version 8; SPSS, Chicago, IL, USA) using a back-
ward stepwise approach; non-significant variables at the
5% level were excluded. Sensitivity analyses were per-
formed to investigate the effect of baseline HbA1c levels on
treatment efficacy. Secondary endpoints and the percent-
age of patients achieving set HbA1c levels were summa-
rised descriptively.
Results
Subjects and baseline characteristics
A total of 528 patients, 183 (35%) with type 1 diabetes
and 345 (65%) with type 2 diabetes, were included in the
analysis (Table 1). Mean HbA1c at baseline before switch-
ing was similar in each group (9.4% and 9.3%, respec-
tively). Overall, 39% of patients with type 1 diabetes and
21% with type 2 diabetes had received bolus insulin doses
in the previous 12 months prior to the switch, whilst 0%
and 38% of patients with type 1 and type 2 diabetes
respectively were taking an OAD.
Change in HbA1c
Mean HbA1c increased in the 12 months prior to the
switch in both diabetic cohorts, by 0.21% (from 9.21% to
9.42%, p > 0.05) in the type 1 cohort and by 0.05%
(9.17% to 9.26%, p > 0.05) in the type 2 cohort (Figure
1A). 12 months after the switch, mean HbA1c was signifi-
cantly lower compared with baseline in each cohort,
decreasing by 0.63% (from 9.42% to 8.79%, p = 0.003) in
patients with type 1 diabetes and by 0.47% (from 9.26%
to 8.79%, p = 0.0004) in patients with type 2 diabetes
(Figure 1B). The greatest decrease in mean HbA1c was
observed in the first 6 months following the switch to a
glargine-based regimen. After adjustment for significant
demographic and clinical covariates, including age,
weight, baseline HbA1c, hypoglycaemia and concomitant
use of OADs, the reduction in mean HbA1c  over 12
months of glargine treatment was 0.67% (p < 0.001) in
the type 1 diabetes cohort and 0.53% in the type 2 diabe-
tes cohort (p < 0.001) (Table 2). Sensitivity analyses
showed that improvement in HbA1c after switching to
glargine was positively correlated with baseline HbA1c.
Patients with baseline HbA1c  ≥ 10% had the greatest
reduction in mean HbA1c (-1.7% in the type 1 diabetes
cohort and -1.2% in the type 2 diabetes cohort) (Table 2).
In each cohort, the reduction in HbA1c did not differ sig-
nificantly by sex, age or weight (data not shown).
Proportion of patients reaching HbA1c levels
Overall, 35% of patients achieved a HbA1c level of 7%
within 12 months of the switch. 32% of the type 1 cohort
and 33% of the type 2 cohort achieved a reduction in
HbA1c ≥ 1%.
Episodes of hypoglycaemia
During the 12 months prior to the switch from premix to
glargine, 105 hypoglycaemic episodes were reported by
the patients with type 1 diabetes (0.57 episodes per
patient/year), while 207 episodes were reported by
patients with type 2 diabetes (0.60 episodes per patient/
year). After switching to glargine, the respective data were
194 episodes for the patients with type 1 diabetes (1.06
episodes per patient/year) and 406 episodes for theCardiovascular Diabetology 2009, 8:9 http://www.cardiab.com/content/8/1/9
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patients with type 2 diabetes (1.18 episodes per patient/
year) during the following 12 months.
Change in use of boluses, total insulin usage and weight
The majority of patients switched from premix to a basal-
bolus glargine regimen. Significant increases in the mean
use of bolus regimens in both diabetic cohorts were
recorded (from 24.6% on premix to 95.1% on glargine in
the type 1 cohort [p < 0.001], and from 16.2% to 73.9%
in the type 2 cohort [p < 0.001], Figure 1C). Switching
from premix to glargine was associated with an increase in
the mean total (glargine + prandial) daily insulin dose in
the type 2 diabetes cohort (from 0.67 ± 1.35 U/Kg to 0.88
± 1.33 U/Kg, p < 0.001) but a slight decrease in the type 1
cohort (from 1.04 ± 2.51 U/Kg to 0.98 ± 2.58 U/Kg, p <
0.001) (Figure 1D). The small initial increase in the first 6
months after the switch in each cohort may be due a
"stock building effect", whereby patients are initially pre-
scribed additional insulin doses to allow them to store a
security stock when starting the treatment with their new
insulin. The use of OADs remained unchanged after the
switch, with quarterly estimates indicating that between
Table 1: Baseline characteristics of patients switching from premix to glargine
Type 1 diabetes Type 2 diabetes
n (%) 183 (35) 345 (65)
% male 53.0 53.0
Age (years)* 22.9 ± 15.5 55.8 ± 16.6
Weight (kg)* 67.7 ± 2.7 85.3 ± 2.2
Baseline HbA1c *† 9.4 ± 1.6 9.3 ± 1.5
Duration of diabetes (years)‡ 7.9 ± 8.7 8.1 ± 6.7
Number of co-morbidities§ 2.5 ± 2.4 2.4 ± 1.9
Premix insulin only (%) 61% 48%
Premix insulin with OAD (%) 0% 38%
Premix + short acting insulin (%) 25% 16%
Premix + basal insulin (%) 8% 5%
Premix + short acting + basal insulin (%) 2% 3%
Premix + other insulin +/-OADs (%) 0% 2%
OADs per patient before starting insulin therapy*¶ - 0.4 ± 0.5
Hypoglycaemia episodes in 3 month period*||
No. episodes 38 72
Mean no. episodes per patient 0.21 0.21
OAD = oral antidiabetic drug; HbA1c = glycated haemoglobin. Data are mean ± SD unless indicated.
*Significant variables investigated in multivariate analysis.
†Data missing for 29 patients with type 1 diabetes and 27 patients with type 2 diabetes.
‡Data missing for 2 patients with type 1 diabetes and 5 patients with type 2 diabetes.
§Includes myocardial infarction, stroke, peripheral vascular disease, neuropathy, nephropathy and retinopathy.
¶Number of oral diabetic treatments (e.g. metformin, sulfonylureas) prescribed prior to commencing insulin.
||Hypoglycaemic episodes reported during the 3 month period prior to switch. Episodes reported in 27 patients with type 1 diabetes and 44 
patients with type 2 diabetes.
Table 2: Adjusted HbA1c reduction over 12 month period in patients switching from premix to glargine*
Variable Type 1 (n = 183) Type 2 (n = 345)
No. Δ HbA1c (%) p-value† No. Δ HbA1c (%) p-value†
Overall 183 -0.67 <0.001 345 -0.53 <0.001
By baseline HbA1c level
≥ 7% 151 -0.67 <0.001 306 -0.56 <0.001
≥ 8% 128 -0.80 <0.001 255 -0.68 <0.001
≥ 9% 86 -1.06 <0.001 169 -0.84 <0.001
≥ 10% 46 -1.74 <0.001 88 -1.20 <0.001
OAD = oral antidiabetic drugs; HbA1c = glycated haemoglobin.
*Adjusted for demographic and clinical covariates including age, weight, hypoglycaemia, concomitant use of OADs and baseline HbA1c (in the 3 
months prior to insulin initiation).
†p-values by the paired t-test for difference in mean HbA1c following switch from premix to glargine.Cardiovascular Diabetology 2009, 8:9 http://www.cardiab.com/content/8/1/9
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34% and 37% of patients received OADs. There was no
significant change in weight in the type 2 cohort (mean
+0.3 kg, from 85.3 ± 2.2 kg to 85.6 ± 2.6 kg, p > 0.05) with
a moderate increase in type 1 patients (mean +3.7 kg,
from 67.6 ± 2.7 kg to 71.3 ± 3.5 kg, p > 0.05).
Discussion
The results from this analysis show that in everyday clini-
cal practice, switching to a basal-bolus glargine-based
insulin regimen improves glycaemic control in patients
with type 1 or type 2 diabetes inadequately controlled on
a premix-based insulin regimen. The overall mean
decrease in HbA1c was 0.67% among type 1 patients and
0.53% among type 2 patients observed 12 months after
switching to a glargine-based regimen.
These findings are supported by data from other observa-
tional studies in patients with type 2 diabetes switching
from premix to glargine-based regimen [14-16] and by a
randomised comparison of a premix-based regimen ver-
sus a glargine-based regimen in type 2 diabetic patients
previously treated with a glargine-based regimen plus
OADs [21]. In this later study, the difference in HbA1c
change after 6 months of treatment was 0.22% in favour
of the glargine-based regimen, approximately half the
decrease noted after 12 months in the type 2 patient
cohort for our study.
Additionally, as far as we are aware, this analysis also pro-
vides the first evidence of a similar benefit in patients with
type 1 diabetes. Sensitivity analyses showed that improve-
Mean HbA1c 12 months before and after switching from premix to glargine (A), mean change in HbA1c after switch (B), mean  use of bolus insulin before and after switch (C) and mean total daily insulin dose before and after switch (D) (unadjusted data) Figure 1
Mean HbA1c 12 months before and after switching from premix to glargine (A), mean change in HbA1c after 
switch (B), mean use of bolus insulin before and after switch (C) and mean total daily insulin dose before and 
after switch (D) (unadjusted data). The last measurement for premix is at -3 months (indicated by vertical dotted line). 
During period -12 m to -3 m patients are taking premix only. During the 3 month switch time point (0 months) patients may be 
prescribed premix and glargine. During period +3 m to +12 m patients are only prescribed glargine (± prandial boluses). Line-
arly interpolated data were used to graphically depict the change in each parameter. Linearly interpolated data affords a clearer 
graphical interpretation but may bias estimates of variance; as such error bars (95% confidence intervals for the means) are not 
reported. Total daily insulin dose was calculated according to the number of units prescribed divided by the number of days 
covered by the prescription.
-12 -9 -6 -3 0 +3 +6 +9 +12
Months since switch
M
e
a
n
 
H
b
A
1
C
 
(
%
)
Type 1 DM
Type 2 DM
8.7
8.9
9.1
9.3
9.5
9.7
A
Months since switch
C
h
a
n
g
e
 
i
n
 
m
e
a
n
 
H
b
A
1
C
 
(
%
)
Type 1 DM
Type 2 DM
- 3 0 + 3+ 6+ 9+ 1 2
-0.8
-0.7
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
B
-12 -9 -6 -3 0 +3 +6 +9 +12
Months since switch
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
b
o
l
u
s
 
(
%
)
Type 1 DM
Type 2 DM
0
20
40
60
80
100
C
-12 -9 -6 -3 0 +3 +6 +9 +12
Months since switch
M
e
a
n
 
t
o
t
a
l
 
d
a
i
l
y
 
d
o
s
e
 
(
U
/
k
g
)
Type 1 DM
Type 2 DM
0.00
0.25
0.50
0.75
1.00
1.25
1.50
DCardiovascular Diabetology 2009, 8:9 http://www.cardiab.com/content/8/1/9
Page 6 of 8
(page number not for citation purposes)
ment in HbA1c was greatest in patients with the poorest
glycaemic control at baseline (mean increase of 1.2% to
1.7% in patients with baseline HbA1c levels ≥ 10%), with
the magnitude of improvement equivalent to that
observed in studies of patients newly commencing insulin
therapy [22]. The United Kingdom Prospective Diabetes
Study showed that a 1% reduction in HbA1C was associ-
ated with a 14% reduction in myocardial infarction, a
14% reduction in all-cause mortality and a 37% reduction
in microvascular complications [23]. Therefore, the reduc-
tion in HbA1C of 0.5 to 0.7% observed in the overall pop-
ulation and ≥ 1% in the sensitivity analysis, achieved by
switching to an insulin glargine-based regimen can be
considered clinically meaningful as these results may
translate to clinical outcomes benefits in the longer-term.
A number of features of this analysis strengthen our find-
ings. Patients included in the analysis had frequent (at
least 3-monthly) follow-up assessment over an extended
period (12 months) before and after switching. Glycaemic
control was evaluated using a uniform, valid, reliable and
widely used measure (HbA1c), which is of relevance to a
real-life clinical practice. Additionally, analysis of changes
in clinical outcomes was assessed by means of linear inter-
polation for missing data and multiple regression tech-
niques to account for factors that may influence the
change in HbA1c. In particular, the multivariate model
attempted to account for the significant increases in the
use of bolus regimens in patients receiving glargine.
However, we do acknowledge a number of limitations.
First, we recognise that retrospective observational studies
do not provide the same robust level of evidence as ran-
domised controlled trials. Countering this, it should be
noted that results from such randomised evaluations may
not translate readily to daily practice for a number of rea-
sons [24,25]. Patients treated within clinical trials gener-
ally receive a higher standard of care than that provided in
daily clinical practice [26,27] and they typically have
restricted inclusion criteria in selected populations which
are generally not representative of those patients treated in
clinical practice. Moreover, findings from a single ran-
domised controlled trial can be subject to substantial pop-
ulation bias which can skew results. These points argue for
the use of observational studies (such as the current anal-
ysis), which are generally well equipped to describe actual
health outcomes in a real-life clinical setting. Health tech-
nology assessment bodies, including the National Insti-
tute of Clinical Excellence in the UK, increasingly seek
data outside the setting of randomised controlled trials
[28]. However, we do acknowledge that the level of data
collection in our analysis did not permit investigation of
various factors that may have influenced our findings,
including certain background characteristics (e.g. ethnic-
ity, body mass index) of the patient population [29-31],
dosing regimen (once vs. twice daily) [32] increased
patient compliance following the switch (e.g. higher
number of general practice visits) and timing of adminis-
tration of glargine (morning vs. bedtime) [33,34]. The
low number of patients included in the study did not per-
mit certain subgroup analyses such as the influence of
prandial boluses on glycaemic control in type 2 patients
switched onto a glargine-based insulin regimen [16].
Second, it was not possible to reliably assess data concern-
ing hypoglycaemic episodes in patients who switch from
a premix-based regimen to a glargine-based regimen. A
lack of consistency in recording these data in the THIN
database meant that there is strong likelihood that we
underestimated the real incidence of hypoglycaemia and
only captured the most severe episodes. The incidence of
hypoglycaemia may also reflect the self-reporting meth-
ods used, as patients and physicians were not requested to
provide specific details of each episode. The limitations of
the database also did not allow assessment of the severity
or nature (e.g. nocturnal) of hypoglycaemic episodes
before and after the switch. A higher number of hypogly-
caemic episodes were noted after the switch from premix
to glargine. Should this trend be real, the significant
improvement in glycaemic control observed with glargine
in both diabetic cohorts and the higher use of bolus regi-
mens in both diabetic cohorts is likely to make patients
more susceptible to episodes of hypoglycaemia. The rea-
son for the slightly higher mean number of hypoglycae-
mic episodes per patient observed in the type 2 cohort
compared with type 1 diabetic cohort is not known and
not in keeping with previous observations.
Third, the decision to switch insulin treatment was not
based on a standard treatment algorithm but instead on
the clinical judgement of individual clinicians, thereby
introducing a subjective bias in the management of
patients in each cohort. Furthermore, as data in this anal-
ysis were included from a large number of general practice
units, this may had led to further heterogeneity in the
data. However, it is possible that the extended period of
assessment (12 months) before and after the switch may
have limited the potential for introduction of bias in our
analysis. In respect of this point, it is reassuring that our
findings are supported by other analyses from different
populations and geographic locations using different
methods of collection of information [14-16]. Finally, as
with any observational study there may be concerns about
missing data. In the current study, interpolated HbA1c data
were available for 87% of patients during the months pre-
ceding and immediately following the switch, decreasing
to 65% of patients during the 12 months after the switch.
Overall, interpolated HbA1c data was used in 60% of
patients. However, the main analysis performed in ourCardiovascular Diabetology 2009, 8:9 http://www.cardiab.com/content/8/1/9
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study was based on the adjusted change in HbA1c which
only used actual and complete data values.
While findings from this analysis suggest that the use of an
glargine-based regimen possibly combining glargine with
either OADs or prandial insulin may be a useful alterna-
tive for improving glycaemic control when other insulin
therapies have failed, there is evidence that glycaemic con-
trol is still suboptimal in UK general practice. In our anal-
ysis, two-thirds of patients remained above a HbA1c level
of 7%, indicating that a large proportion of patients do
not reach preferred target levels. This could indicate that
the initiation of insulin was possibly too late and that
additional treatment strategies are needed. This may
include more aggressive titration with insulin glargine (in
the current analysis glargine treatment had no significant
effect on weight despite a moderate increase for the type 1
patients suggesting suboptimal treatment), greater use of
OAD therapy in patients with type 2 diabetes (only 38%
were receiving OAD therapy at baseline and 35% at 12
months), additional doses of prandial insulin and the use
of educational programs [16,35-37].
Conclusion
This retrospective analysis shows that switching from
premix to a basal-bolus glargine-based insulin regimen
improves glycaemic control substantially. Given the cave-
ats associated with retrospective data collection, our find-
ings suggest that this approach may be useful in a clinical
practice setting for the management of patients in whom
premix is suboptimally effective or poorly tolerated.
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